

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/006756 A2

(51) International Patent Classification⁷: **A61B**
(21) International Application Number:
PCT/US2003/022440
(22) International Filing Date: 17 July 2003 (17.07.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/396,393 17 July 2002 (17.07.2002) US
(71) Applicant (for all designated States except US): **BIOGEN INC.** [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventor; and
(75) Inventor/Applicant (for US only): **LOBB, Roy, R.** [US/US]; 569 Canton Street, Westwood, MA 02090 (US).
(74) Agents: **CLAUSS, Isabelle, M et al.**; Patent Group, Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210 (US).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPIES FOR RENAL FAILURE USING INTERFERON- β

(57) Abstract: The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, glomerulonephritis or chronic renal failure. The methods involve the administration of IFN- β therapeutics.

BEST AVAILABLE COPY

WO 2004/006756 A2